Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corporation filed Post-Effective Amendment No. 5 to its Form S-1 to register up to 65,068 shares of Common Stock for resale by selling securityholders, consisting of (i) up to 22,952 Private Placement Warrant Shares, (ii) up to 2,800 PIPE Warrant Shares and (iii) 39,316 other shares. The company states it will receive proceeds only if the Warrants are exercised; full cash exercise of all Warrants would generate approximately $74.0 million. SeaStar discloses prior reverse stock splits (1-for-25 in 2024; 1-for-10 in 2026), Nasdaq listings under symbols ICU and ICUCW, and that 3,997,002 shares were outstanding as of April 20, 2026. The filing also reports the dismissal with prejudice of a putative class action on April 27, 2026 and ongoing derivative litigation that remains stayed or unresolved.
SeaStar Medical Holding Corporation amends its effective Form S-1 to register for resale up to 1,091,730 shares of Common Stock issuable upon exercise of certain private placement and placement-agent warrants (the “Resale Shares”).
The prospectus states the resale registration covers: up to 524,249 July Common Warrant Shares, 36,699 July Placement Agent Warrant Shares, 496,057 August Common Warrant Shares and 34,725 August Placement Agent Warrant Shares. The company will not receive proceeds from resales by the selling securityholders but would receive proceeds from any cash exercises of the Warrants. Shares outstanding were 3,997,002 as of April 20, 2026.
SeaStar Medical Holding Corporation files a Post-Effective Amendment No. 1 to its Form S-1 to incorporate by reference prior and future SEC filings and to update the prospectus; no additional securities are being registered in this amendment. The prospectus covers an offering that includes 493,542 shares of Common Stock, accompanying Series A and Series B Warrants, 66,232 Pre-Funded Warrants, and 43,079 Placement Agent Warrants, together representing 1,340,091 shares issuable upon exercise. The filing restates offering terms (combined offering price $6.50 per share/unit; Pre-Funded Warrant price $6.499), notes a 1-for-10 reverse split effective January 5, 2026, and discloses that a putative class action and a derivative action were dismissed (the class complaint was dismissed with prejudice by court order on April 27, 2026). The prospectus states estimated net proceeds of approximately $3.39 million under specified assumptions and that aggregate cash proceeds on full cash exercise of outstanding warrants would be approximately $8.4 million.
SeaStar Medical Holding Corporation is filing an S-1 to register the resale of up to 1,664,543 shares of common stock held by Lincoln Park Capital Fund LLC. These shares relate to a previously signed $15.0 million equity purchase agreement, under which SeaStar can periodically sell stock to Lincoln Park.
SeaStar will not receive proceeds from Lincoln Park’s resale of these registered shares, but may receive up to an additional $14,657,887.43 in gross proceeds from future share sales to Lincoln Park under the agreement. As of April 20, 2026, the company had 3,997,002 shares outstanding, and sales under this structure, alongside past at-the-market offerings, could dilute existing holders.
The filing also describes SeaStar’s commercial-stage inflammatory disease platform, including its FDA-approved pediatric SCD therapy under a Humanitarian Device Exemption, multiple Breakthrough Device Designations, and ongoing adult clinical programs targeting acute kidney injury and cardiorenal indications.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.
SeaStar Medical Holding Corporation is a commercial-stage healthcare company developing its Selective Cytopheretic Device (SCD) to treat life‑threatening hyperinflammatory conditions that drive acute and chronic organ failure. The SCD modulates over‑active neutrophils and monocytes via an extracorporeal membrane integrated into continuous renal replacement therapy systems.
In February 2024, the FDA approved the pediatric SCD therapy QUELIMMUNE under a Humanitarian Device Exemption for acute kidney injury due to sepsis, and commercial shipments began in July 2024. As of December 31, 2025, 10 hospitals had completed the required SAVE Surveillance Registry and purchased QUELIMMUNE, with early registry data in 21 patients showing no device‑related safety events and favorable 60‑ and 90‑day survival.
For adults, the pivotal NEUTRALIZE‑AKI trial in ICU patients with acute kidney injury on CRRT targets 339 subjects, with 181 enrolled as of March 21, 2026. The SCD platform has received multiple FDA Breakthrough Device Designations across acute kidney injury, cardiorenal and hepatorenal syndromes, end‑stage renal disease, and cardiac surgery–related systemic inflammation, supported by a patent estate of 17 U.S. and 29 foreign patents.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.
SeaStar Medical Holding Corp received an updated ownership report from investors Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of December 31, 2025, they report beneficial ownership of 3,980,665 shares of common stock, equal to 9.99% of the class.
The position is entirely through six warrants held by Intracoastal. Three warrants are counted, while three additional warrants are contractually blocked from exercise above 9.99% or 4.99% ownership caps. Without these blocker provisions, their beneficial ownership would be 5,342,845 shares. The group states the holdings are not for changing or influencing control of SeaStar Medical.
SeaStar Medical Holding Corp director Kenneth Van Heel reported receiving a grant of restricted stock units (RSUs) under the company’s equity program. On February 6, 2026, he acquired 3,000 shares of common stock at a price of $0 as an award.
According to the filing, these RSUs will vest in full on February 6, 2027, meaning the shares become fully owned on that date if vesting conditions are met. After this grant, Van Heel beneficially owns 7,940 shares of SeaStar Medical common stock directly.
SeaStar Medical Holding Corp director John Neuman reported a stock-based award. On February 6, 2026, he received 3,000 shares of common stock at a stated price of $0, reported as an acquired transaction.
After this grant, Neuman beneficially owns 12,200 shares of SeaStar Medical common stock in direct form. The filing notes that the 3,000-share award represents restricted stock units (RSUs) that will vest in full on February 6, 2027.